Pfizer (PFE) Long-Term Investments (2016 - 2025)
Pfizer (PFE) has disclosed Long-Term Investments for 17 consecutive years, with $2.1 billion as the latest value for Q3 2025.
- On a quarterly basis, Long-Term Investments fell 1.97% to $2.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 billion, a 1.97% decrease, with the full-year FY2024 number at $2.2 billion, down 40.28% from a year prior.
- Long-Term Investments was $2.1 billion for Q3 2025 at Pfizer, up from $224.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $21.6 billion in Q4 2021 to a low of $224.0 million in Q1 2025.
- A 5-year average of $9.0 billion and a median of $7.9 billion in 2024 define the central range for Long-Term Investments.
- Peak YoY movement for Long-Term Investments: skyrocketed 428.58% in 2021, then tumbled 97.17% in 2025.
- Pfizer's Long-Term Investments stood at $16.5 billion in 2021, then tumbled by 34.29% to $10.8 billion in 2022, then crashed by 65.53% to $3.7 billion in 2023, then plummeted by 40.28% to $2.2 billion in 2024, then decreased by 4.08% to $2.1 billion in 2025.
- Per Business Quant, the three most recent readings for PFE's Long-Term Investments are $2.1 billion (Q3 2025), $224.0 million (Q2 2025), and $224.0 million (Q1 2025).